Abstract: The present invention relates to a pharmaceutical composition for oral administration comprising: a) about 5% w/w to about 40% w/w of lumateperone or pharmaceutically acceptable salt thereof; b) about 50% w/w to about 95% w/w of at least one diluent; c) about 1% w/w to about 10% w/w of at least one disintegrant; d) about 0.1% w/w to about 2% w/w of at least one glidant; and e) about 0.5% w/w to about 5% w/w of a lubricant selected from the group consisting of sodium stearyl fumarate, stearic acid, and combinations thereof, wherein the amount of nitrosamine impurity after exposure of the pharmaceutical composition to 40° C./75% RH for a period of six months is less than the FDA acceptable intake limit of the nitrosamine impurity based on maximum daily dose of lumateperone.

Abstract: The present invention relates to a stable pharmaceutical composition of Topiramate and process for the preparation thereof. This invention more particularly relates to a stable aqueous pharmaceutical composition comprising Topiramate and process for the preparation thereof.

Abstract: The present invention relates to a stable aqueous solution composition suitable for oral administration comprising nimodipine, polyethylene glycol, dehydrated alcohol, glycerin, water and preservative.